Cochrane2024Ia
Cochrane Review: Metformin for preventing the progression of chronic kidney disease
Zusammenfassung
Metformin zur Vorbeugung der Verschlechterung einer chronischen Nierenerkrankung - El-Damanawi, R - 2024 \| Cochrane Library
[Skip to Content](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013414.pub2/full/de#main-content)
[Close cookies message](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013414.pub2/full/de#)
Cookies
Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how
Kerninformationen
e Database of Systematic reviews](https://www.cochranelibrary.com/en/about/about-cochrane-reviews) Review - Intervention
Collapse all Expand all
## Abstract
available in
### Background
Metformin has been used in the management of diabetes for decades. It is an effective, low‐cost intervention ...
earched the Cochrane Kidney and Transplant Register of Studies up to 19 July 2023 with assistance from an Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the Internatio...
cal interventions, other antidiabetic medications or any other active control.
Studies that included patients on any modality of kidney replacement therapy were excluded.
### Data collection and analysis
Two authors independently carried out data extraction using a standard data extraction form. ...
Fragen zu diesem Thema?
ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.
Jetzt auf ClariMed suchenVerwandte Leitlinien
Cochrane2020
Cochrane Review: Metformin monotherapy for adults with type 2 diabetes mellitus
Cochrane2019
Cochrane Review: Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
Cochrane2024
Cochrane Review: Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
Cochrane2025
Cochrane Review: Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes
Cochrane2020